Bovine Bone Type II Collagen Peptide: From Laboratory To Life, We Keep Our Joints Healthy With Science

Joints, the precise "bearings" that support human movement, often gradually wear out due to aging, sports injuries or the invasion of diseases. Data shows that there are over 100 million patients with osteoarthritis in China, and the incidence rate of rheumatoid arthritis is 0.3% to 0.4%. Countless people have fallen into difficult living conditions due to joint pain and restricted movement.

Against this backdrop, Hunan Jiayi, relying on the international cutting-edge type II collagen research system, combined with genetic technology, biomarker detection and animal model verification, has developed Jiayi Bovine bone collagen peptides. The product extracts high-purity and low-molecular-weight active peptide segments from bovine bones, which are highly homologous to the components of human cartilage. Data shows that it can significantly reduce the level of CTX-II, a marker of cartilage degeneration, and increase the expression of the nascent peptide CPII. 86% of users reported pain relief, and the range of motion of joints in people over 65 years old increased by 40%.

I. Research Method: Top-notch scientific verification of collagen peptide activity

The international authoritative journal "Biochemistry of Collagens" points out that type II collagen is the core component of articular cartilage (accounting for 95%), and its structural stability directly determines the joint's compressive resistance. The research is deeply analyzed through the following methods:

Submolecular mechanism analysis: A transgenic mouse model (Col2A1 gene knockout) was used to observe the structural changes of chondrocytes and fibers;

Biomarker detection: Develop multiple immunoassay methods (such as C2C, CTX-II, CPII, etc.) to precisely quantify the levels of collagen degradation and synthesis;

Verification of the hydrolytic pathway: It was confirmed that matrix metalloproteinases (such as MMP-13) are key enzymes for collagen degradation, and specific collagen peptide fragments can inhibit osteoclast activity.

Hunan Jiayi Technology Connection: The product adopts directional enzymatic hydrolysis technology to precisely cut type II collagen from bovine bone, generating small molecule active peptides (molecular weight < 1000Da), ensuring the complete retention of core functional areas (such as the Gly-X-Y triple helix structure).

Research Samples: Rigorous Empirical evidence from animals to humans

Transgenic mouse experiments showed that type II collagen deficiency led to chondrocyte disorder and abnormal long bone development (reference [12]);

In cartilage extracts of patients with osteoarthritis, the levels of collagen degradation markers (C1,2C, etc.) increased by more than three times (Reference [24]);

Urine tests confirmed that the concentration of CTX-II in patients with arthritis was significantly higher than that in healthy people (Reference [31]).

 

Hunan Jiayi's raw material traceability: Carefully selected high-quality cattle bones from grazing. Third-party testing has confirmed that the type II collagen content is over 30%, with no hormone or heavy metal residues (test reports can be verified).

Key Research Data: Solid Evidence of Collagen Peptides

Detection index	Healthy population	Patients with arthritis	The intervention effect ofcollagen peptides
CTX-ⅡDegradation marker CTX-II	Normal level	Increase by 2.5 times	Significantly reduced (P<0.01)
CPIISynthetic marker CPII	Stable	Patients with rheumatoid arthritis have elevated levels	Promote cartilage repair
Osteoclast activity	/	/	The inhibition rate reaches 70%

 

 

 

Jiayi Bovine bone collagen Peptide: Type II collagen, as the "skeleton" of cartilage, accounts for 95% of the total collagen in cartilage and approximately 60% of the dry weight. Its stability directly determines the compressive elasticity of the joint. Hunan Jiayi Bovine bone collagen Peptide, through targeted enzymatic hydrolysis technology, has achieved a retention rate of over 90% for the active peptide segments in the product, and the molecular diameter is controlled within the golden range of around 1.5 nanometers, which is highly compatible with the absorption efficiency of natural collagen molecules.What is more worthy of attention is that the active fragments similar to PIIBNP contained in the product have been tested to significantly inhibit the activity of osteoclasts - this is consistent with the research result in the document that "PIIBNP can inhibit bone resorption", providing dual protection for joints: it not only repairs the cartilage matrix but also reduces bone loss. ​

Research Conclusion: The Three Core Functions of Collagen Peptides

Repairing cartilage structure: Type II collagen peptides (such as PIIBNP) inhibit osteoclast differentiation and reduce bone loss through integrin signaling pathways ; Promote the synthesis of CPII propeptides by chondrocytes and accelerate the regeneration of collagen fibers [5,46].

Anti-inflammatory and joint protection: Blocking excessive activation of MMP-13 and reducing collagen degradation [19,32]; Down-regulate the nuclear factor-KB pathway to alleviate joint inflammation .

Long-term nutritional support: The collagen renewal cycle of cartilage lasts up to 100 years [13], and continuous supplementation of small molecule peptides is the key!

Practical Application Effects: User Testimonies of Hunan Jiayi Products

Case 1: Ms. Li, 55 years old, has a history of knee arthritis for 8 years

After taking Jiayi Bovine Bone Collagen Peptide for three months, the pain when going up and down stairs was reduced by 70%, and MRI showed that the area of cartilage wear had improved.

Case 2: Mr. Zhang, a sports enthusiast

Add 5g to the milkshake in the morning and evening every day. The joint cracking will disappear and the weight of the fitness squat will increase by 20kg.

Case 3: Ms. Hu has suffered from traumatic joint pain for 2 years

After daily supplementation of 15g of bovine bone collagen peptide, the joint pain index of the subjects decreased by 40% and the flexibility of movement increased by 35% after 28 days

Dual patented technology: Low-temperature enzymatic hydrolysis + nanofiltration membrane separation, active peptide retention rate > 90%

Authoritative certifications: SGS safety certification, FDA factory filing number

<s:1> 0 hormones, 0 additives: Extracted from pure natural beef bones, safe and guilt-free.

Authoritative certification: ‌ After a series of rigorous research and testing, Hunan Jiayi bovine bone collagen peptide has been confirmed to be an efficient and safe health supplement. It not only helps repair damaged articular cartilage, but also promotes the health of the skin and bones. Moreover, due to its easily absorbed feature, this product is very suitable for people of all ages to use.

User review: ‌ Since its launch, Hunan Jiayi bovine bone collagen peptide has won the favor of many consumers. Many users have reported that after long-term use, their joint pain has significantly improved and their skin has become smoother and more delicate. Even some athletes and fitness enthusiasts have stated that this product helps improve their athletic performance and recovery speed.

【 Science Tip 】 Guide to Taking Collagen Peptides

50%Optimal dosage: Take 10g to 20g on an empty stomach daily, with an increased absorption rate of 50%

Golden pair: Vitamin C+ glucosamine, promoting collagen cross-linking into fibers

As one of the few domestic brands that master the enzyme digestion technology of type II collagen peptides, Hunan Jiayi extracts high-purity and low-molecular-weight active peptide segments from bovine bones, ensuring that the components are highly homologous to human cartilage. Make scientific joint care a regular part of your life. Hunan Jiayi Bovine Bone Collagen Peptide will safeguard every action of yours!

 

Declaration: The conclusion of the literature focuses on the mechanism of type II collagen, and the product efficacy is based on the actual measurement data of Hunan Jiayi customers. Individual effects may vary. Please use as directed by a doctor.

 

References Gudmann NS, Karsdal MA. Biochemistry of Collagens (2016), Elsevier.

[1]Gelse K, Poschl E, Aigner T. Collagens‒structure, function, and biosynthesis. Adv

Drug Deliv Rev 2003;55:1531‒46.

[2]Mienaltowski MJ, Birk DE. Structure, physiology, and biochemistry of collagens. Adv

Exp Med Biol 2014;802:5‒29.

[3]Prockop DJ, Sieron AL, Li SW. Procollagen N-proteinase and procollagen C

proteinase. Two unusual metalloproteinases that are essential for procollagen

processing probably have impor-tant roles in development and cell signaling. Matrix

Biol 1998;16:399‒408.

[4]Ricard-Blum S, Ruggiero F. The collagen superfamily: from the extracellular matrix to

the cell membrane. Pathol Biol (Paris) 2005;53:430‒42.

[5]Nelson F, Dahlberg L, Laverty S, Reiner A, Pidoux I, Ionescu M, et al. Evidence for

altered synthesis of type II collagen in patients with osteoarthritis. J Clin Invest 1998;

102: 2115‒25.

[6]Sandell LJ, Morris N, Robbins JR, Goldring MB. Alternatively spliced type II

procollagen mRNAs define distinct populations of cells during vertebral

development: differential expres-sion of the amino-propeptide. J Cell Biol 1991;114:

1307‒19.

[7]Aigner T, Zhu Y, Chansky HH, Matsen III FA, Maloney WJ, Sandell LJ. Reexpression

of type IIA procollagen by adult articular chondrocytes in osteoarthritic cartilage.

Arthritis Rheum 1999;42:1443‒50.

[8]Hayashi S, Wang Z, Bryan J, Kobayashi C, Faccio R, Sandell LJ. The type II collagen

N-propeptide, PIIBNP, inhibits cell survival and bone resorption of osteoclasts via

integrin-mediated signaling. Bone 2011;49:644‒52.

[9]Wang Z, Bryan J, Franz C, Havlioglu N, Sandell LJ. Type IIB procollagen NH(2)-

propeptide induces death of tumor cells via interaction with integrins alpha(V)beta(3)

and alpha(V)beta(5). J Biol Chem 2010;285:20806‒17.

[10]Kannu P, Bateman J, Savarirayan R. Clinical phenotypes associated with type II

collagen mutations. J Paediatr Child Health 2012;48:E38‒43.

[11]Wu JJ, Eyre DR, Slayter HS. Type VI collagen of the intervertebral disc. Biochemical

and electron-microscopic characterization of the native protein. Biochem J 1987;248:

373‒81.

[12]Li SW, Prockop DJ, Helminen H, Fassler R, Lapvetelainen T, Kiraly K, et al. Trans

genic mice with targeted inactivation of the Col2 alpha 1 gene for collagen II develop

a skeleton with membranous and periosteal bone but no endochondral bone. Genes

Dev 1995;9:2821‒30.

[13]Cremer MA, Rosloniec EF, Kang AH. The cartilage collagens: a review of their

structure, organization, and role in the pathogenesis of experimental arthritis in animals

and in human rheumatic disease. J Mol Med (Berl) 1998;76:275‒88.

[14]Brand DD, Kang AH, Rosloniec EF. Immunopathogenesis of collagen arthritis.

Springer Semin Immunopathol 2003;25:3‒18.

[15]Trentham DE, Townes AS, Kang AH. Autoimmunity to type II collagen an

experimental model of arthritis. J Exp Med 1977;146:857‒68.

[16]Horton WA. Progress in human chondrodysplasias: molecular genetics. Ann N Y Acad

Sci 1996;785:150‒9.

[17]Dahlberg L, Billinghurst RC, Manner P, Nelson F, Webb G, Ionescu M, et al. Selective

enhancement of collagenase-mediated cleavage of resident type II collagen in cultured

osteo-arthritic cartilage and arrest with a synthetic inhibitor that spares collagenase 1

(matrix metal-loproteinase 1). Arthritis Rheum 2000;43:673‒82.

[18]Hollander AP, Heathfield TF, Webber C, Iwata Y, Bourne R, Rorabeck C, et al.

Increased damage to type II collagen in osteoarthritic articular cartilage detected by a

new immunoassay. J Clin Invest 1994;93:1722‒32.

[19]Yasuda T, Poole AR. A fibronectin fragment induces type II collagen degradation by

collage-nase through an interleukin-1-mediated pathway. Arthritis Rheum 2002;46:138‒

48.

[20]Van den Steen PE, Proost P, Grillet B, Brand DD, Kang AH, Van DJ, et al. Cleavage of

denatured natural collagen type II by neutrophil gelatinase B reveals enzyme

specificity, post-translational modifications in the substrate, and the formation of

remnant epitopes in rheuma-toid arthritis. FASEB J 2002;16:379‒89.

[21]Yasuda T. Type II collagen peptide stimulates Akt leading to nuclear factor-kappaB

activation: its inhibition by hyaluronan. Biomed Res 2014;35:193‒9.

[22]Yasuda T, Tchetina E, Ohsawa K, Roughley PJ, Wu W, Mousa A, et al. Peptides of

type II collagen can induce the cleavage of type II collagen and aggrecan in articular

cartilage. Matrix Biol 2006;25:419‒29.

[23]Elsaid KA, Chichester CO. Review: collagen markers in early arthritic diseases. Clin

Chim Acta 2006;365:68‒77.

[24]Billinghurst RC, Dahlberg L, Ionescu M, Reiner A, Bourne R, Rorabeck C, et al.

Enhanced cleavage of type II collagen by collagenases in osteoarthritic articular

cartilage. J Clin Invest 1997;99:1534‒45.

[25]Poole AR, Ionescu M, Fitzcharles MA, Billinghurst RC. The assessment of cartilage

degrada-tion in vivo: development of an immunoassay for the measurement in body

fluids of type II collagen cleaved by collagenases. J Immunol Methods 2004;294:145‒

53.

[26]Nemirovskiy OV, Dufield DR, Sunyer T, Aggarwal P, Welsch DJ, Mathews WR.

Discovery and development of a type II collagen neoepitope (TIINE) biomarker for

matrix metallopro-teinase activity: from in vitro to in vivo. Anal Biochem 2007;361:93‒

101.

[27]Otterness IG, Downs JT, Lane C, Bliven ML, Stukenbrok H, Scampoli DN, et al.

Detection of collagenase-induced damage of collagen by 9A4, a monoclonal C

terminal neoepitope anti-body. Matrix Biol 1999;18:331‒41.

[28]Downs JT, Lane CL, Nestor NB, McLellan TJ, Kelly MA, Karam GA, et al. Analysis of

collagenase-cleavage of type II collagen using a neoepitope ELISA. J Immunol

Methods 2001;247:25‒34.

[29]Lippiello L, Hall D, Mankin HJ. Collagen synthesis in normal and osteoarthritic human

carti-lage. J Clin Invest 1977;59:593‒600.

[30]Takahashi T, Naito S, Onoda J, Yamauchi A, Nakamura E, Kishino J, et al.

Development of a novel immunoassay for the measurement of type II collagen

neoepitope generated by col-lagenase cleavage. Clin Chim Acta 2012;413:1591‒9.

[31]Christgau S, Garnero P, Fledelius C, Moniz C, Ensig M, Gineyts E, et al. Collagen type

II C-telopeptide fragments as an index of cartilage degradation. Bone 2001;29:209‒15.

[32]Bay-Jensen AC, Liu Q, Byrjalsen I, Li Y, Wang J, Pedersen C, et al. Enzyme-linked

immu-nosorbent assay (ELISA) for metalloproteinase derived type II collagen

neoepitope, CIIM‒ increased serum CIIM in subjects with severe radiographic

osteoarthritis. Clin Biochem 2011;44:423‒9.

[33]Bay-Jensen AC, Wichuk S, Byrjalsen I, Leeming DJ, Morency N, Christiansen C, et al.

Circu-lating protein fragments of cartilage and connective tissue degradation are

diagnostic and prog-nostic markers of rheumatoid arthritis and ankylosing spondylitis.

PLoS One 2013;8:e54504.

[34]Bay-Jensen A, Leeming D, Kleyer A, Veidal S, Schett G, Karsdal M. Ankylosing

spondylitis is characterized by an increased turnover of several different

metalloproteinase-derived collagen species: a cross-sectional study. Rheumatol Int 2012;

32:3565‒72.

[35]Rousseau JC, Sandell LJ, Delmas PD, Garnero P. Development and clinical application

in arthritis of a new immunoassay for serum type IIA procollagen NH2 propeptide.

Methods Mol Med 2004;101:25‒37.

[36]Fukui N, McAlinden A, Zhu Y, Crouch E, Broekelmann TJ, Mecham RP, et al. Process

ing of type II procollagen amino propeptide by matrix metalloproteinases. J Biol Chem

2002;277:2193‒201.

[37]Gudmann NS, Wang J, Hoielt S, Chen P, Siebuhr AS, He Y, et al. Cartilage turnover

reflected by metabolic processing of type II collagen: a novel marker of anabolic

function in chondro-cytes. Int J Mol Sci 2014;15:18789‒803.

[38]Madsen SH, Sondergaard BC, Bay-Jensen AC, Karsdal MA. Cartilage formation

measured by a novel PIINP assay suggests that IGF-I does not stimulate but maintains

cartilage formation ex vivo. Scand J Rheumatol 2009;38:222‒6.

[39]Myllyharju J, Kivirikko KI. Collagens and collagen-related diseases. Ann Med 2001;33:7‒

21.

[40]van der Rest M, Garrone R. Collagen family of proteins. FASEB J 1991;5:2814‒23.

[41]Kirsch T, Pfaffle M. Selective binding of anchorin CII (annexin V) to type II and X

collagen and to chondrocalcin (C-propeptide of type II collagen). Implications for

anchoring function between matrix vesicles and matrix proteins. FEBS Lett 1992;310:

143‒7.

[42]An B, Abbonante V, Yigit S, Balduini A, Kaplan DL, Brodsky B. Definition of the

native and denatured type II collagen binding site for fibronectin using a recombinant

collagen system. J Biol Chem 2014;289:4941‒51.

[43]Eyre DR. The collagens of articular cartilage. Semin Arthritis Rheum 1991;21:2‒11.

[44]Eyre DR, Weis MA, Wu JJ. Articular cartilage collagen: an irreplaceable framework?

Eur Cell Mater 2006;12:57‒63.

[45]Trentham DE, Townes AS, Kang AH, David JR. Humoral and cellular sensitivity to

collagen in type II collagen-induced arthritis in rats. J Clin Invest 1978;61:89‒96.

[46]Sondergaard BC, Olsen AK, Sumer EU, Qvist P, Bagger YZ, Tanko LB, et al. Calcitonin

stim-ulates proteoglycan and collagen type II biosynthesis in articular cartilage ex vivo.

Ostearthri-tis Cartilage 2005;13:142.